Hide metadata

dc.date.accessioned2022-03-12T18:33:26Z
dc.date.available2022-03-12T18:33:26Z
dc.date.created2021-09-22T17:31:29Z
dc.date.issued2021
dc.identifier.citationY-Hassan, Shams Sörensson, Peder Ekenbäck, Christina Lundin, Magnus Agewall, Stefan Brolin, Elin Bacsovics Caidahl, Kenneth Cederlund, Kerstin Collste, Olov Daniel, Maria Jensen, Jens Hofman-Bang, Claes Lyngå, Patrik Maret, Eva Sarkar, Nondita Spaak, Jonas Winnberg, Oscar Ugander, Martin Tornvall, Per Henareh, Loghman . Plasma catecholamine levels in the acute and subacute stages of takotsubo syndrome: Results from the Stockholm myocardial infarction with normal coronaries 2 study. Clinical Cardiology. 2021
dc.identifier.urihttp://hdl.handle.net/10852/92407
dc.description.abstractAims It is well-accepted that takotsubo syndrome (TS) is characterized by a massive surge of plasma catecholamines despite lack of solid evidence. The objective of this study was to examine the hypothesis of a massive catecholamine elevation in TS by studying plasma-free catecholamine metabolites in patients participating in the Stockholm myocardial infarction (MI) with normal coronaries 2 (SMINC-2) study where TS constituted more than one third of the patients. Methods and results The patients included in the SMINC-2 study were classified, according to cardiac magnetic resonance (CMR) imaging findings (148 patients), which was performed at a median of 3 days after hospital admission. Plasma-free catecholamine metabolites; metanephrine, normetanephrine, and methoxy-tyramine were measured on day 2–4 after admission. Catecholamine metabolite levels were available in 125 patients. One hundred and ten (88%) of the 125 patients included in SMINC-2 study, and 38 (86.4%) of the 44 patients with TS had completely normal plasma metanephrine and normetanephrine levels. All patients had normal plasma methoxy-tyramine levels. Fourteen (11.2%) of the 125 patients included in SMINC-2 study, and 5 (11.6%) of the 43 patients with TS had mild elevations (approximately 1.2 times the upper normal limits) of either plasma metanephrine or normetanephrine. One patient with pheochromocytoma-triggered TS had marked elevation of plasma metanephrine and mild elevation of plasma normetanephrine. There were no significant differences between the number or degree of catecholamine metabolite elevations between the different groups of patients with CMR imaging diagnosis included in SMINC-2 study. Conclusion There was no evidence of massive catecholamine elevations in the acute and subacute stages of TS apart from one patient with pheochromocytoma-induced TS. Most of the TS patients had normal catecholamine metabolites indicating that blood-borne catecholamines do not play a direct role in the pathogenesis of TS.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titlePlasma catecholamine levels in the acute and subacute stages of takotsubo syndrome: Results from the Stockholm myocardial infarction with normal coronaries 2 study
dc.typeJournal article
dc.creator.authorY-Hassan, Shams
dc.creator.authorSörensson, Peder
dc.creator.authorEkenbäck, Christina
dc.creator.authorLundin, Magnus
dc.creator.authorAgewall, Stefan
dc.creator.authorBrolin, Elin Bacsovics
dc.creator.authorCaidahl, Kenneth
dc.creator.authorCederlund, Kerstin
dc.creator.authorCollste, Olov
dc.creator.authorDaniel, Maria
dc.creator.authorJensen, Jens
dc.creator.authorHofman-Bang, Claes
dc.creator.authorLyngå, Patrik
dc.creator.authorMaret, Eva
dc.creator.authorSarkar, Nondita
dc.creator.authorSpaak, Jonas
dc.creator.authorWinnberg, Oscar
dc.creator.authorUgander, Martin
dc.creator.authorTornvall, Per
dc.creator.authorHenareh, Loghman
cristin.unitcode185,53,11,10
cristin.unitnameHjertemedisinsk avdeling
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1937322
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical Cardiology&rft.volume=&rft.spage=&rft.date=2021
dc.identifier.jtitleClinical Cardiology
dc.identifier.volume44
dc.identifier.issue11
dc.identifier.startpage1567
dc.identifier.endpage1574
dc.identifier.pagecount0
dc.identifier.doihttps://doi.org/10.1002/clc.23723
dc.identifier.urnURN:NBN:no-94972
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn0160-9289
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/92407/4/Clinical-Cardiology-2021-Hassan.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International